NASDAQ:HBIO - Harvard Bioscience Stock Price, Price Target & More

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its quarterly earnings data on Wednesday, May, 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The medical instruments supplier had revenue of $26.76 million for the quarter, compared to the consensus estimate of $27.50 million. Harvard Bioscience had a negative net margin of 3.70% and a positive return on equity of 2.79%. View Harvard Bioscience's Earnings History.

Harvard Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Harvard Bioscience.

2 brokers have issued 12-month price objectives for Harvard Bioscience's shares. Their forecasts range from $8.00 to $11.00. On average, they expect Harvard Bioscience's stock price to reach $9.50 in the next year. This suggests a possible upside of 86.3% from the stock's current price. View Analyst Ratings for Harvard Bioscience.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Harvard Bioscience include Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

Media stories about HBIO stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Harvard Bioscience earned a news impact score of 0.04 on Accern's scale. They also gave headlines about the medical instruments supplier an impact score of 46.93 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Harvard Bioscience's stock is owned by many different of institutional and retail investors. Top institutional investors include Foundry Partners LLC (1.17%). Company insiders that own Harvard Bioscience stock include David Green, Earl R Lewis, George Uveges, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Institutional Ownership Trends for Harvard Bioscience.

HBIO stock was sold by a variety of institutional investors in the last quarter, including Foundry Partners LLC. Company insiders that have sold Harvard Bioscience company stock in the last year include George Uveges, Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HBIO stock can currently be purchased for approximately $5.10.

Harvard Bioscience has a market capitalization of $185.30 million and generates $101.88 million in revenue each year. The medical instruments supplier earns $-860,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Harvard Bioscience employs 434 workers across the globe.

Harvard Bioscience's mailing address is 84 OCTOBER HILL ROAD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected]